| 1.29 -0.07 (-5.15%) | 07-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.69  |
1-year : | 1.91 |
| Resists | First : | 1.45 |
Second : | 1.63 |
| Pivot price | 1.29 |
|||
| Supports | First : | 1.14 |
Second : | 0.95 |
| MAs | MA(5) : | 1.28 | MA(20) : | 1.29 |
| MA(100) : | 1.32  |
MA(250) : | 2.08 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 20.7 |
D(3) : | 21.1 |
| RSI | RSI(14): 51.9 | |||
| 52-week | High : | 3.42 | Low : | 0.93 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AKYA ] has closed above bottom band by 41.2%. Bollinger Bands are 73.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.29 - 1.3 | 1.3 - 1.3 |
| Low: | 1.27 - 1.28 | 1.28 - 1.29 |
| Close: | 1.28 - 1.29 | 1.29 - 1.3 |
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Tue, 08 Jul 2025
Quanterix completes acquisition of Akoya Biosciences, delisting set from Nasdaq - Investing.com
Wed, 21 May 2025
Akoya Biosciences reviews unsolicited acquisition proposal - Investing.com
Wed, 14 May 2025
Quanterix: Hard To Make A Good Diagnosis (NASDAQ:QTRX) - Seeking Alpha
Mon, 12 May 2025
Akoya Biosciences Reports First Quarter 2025 Financial Results - GlobeNewswire
Thu, 24 Apr 2025
Akoya Biosciences and Enable Medicine Launch the Largest - GlobeNewswire
Mon, 24 Mar 2025
Tikvah Management Announces Intention to Vote AGAINST Quanterix’s Proposed Merger with Akoya Biosciences - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 50 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 72.5 (%) |
| Held by Institutions | 69.8 (%) |
| Shares Short | 2,640 (K) |
| Shares Short P.Month | 2,400 (K) |
| EPS | -0.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.12 |
| Profit Margin | -59.5 % |
| Operating Margin | -79.8 % |
| Return on Assets (ttm) | -17.5 % |
| Return on Equity (ttm) | -354.3 % |
| Qtrly Rev. Growth | -9.4 % |
| Gross Profit (p.s.) | 0.98 |
| Sales Per Share | 1.6 |
| EBITDA (p.s.) | -0.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -1.35 |
| PEG Ratio | 0 |
| Price to Book value | -10.75 |
| Price to Sales | 0.8 |
| Price to Cash Flow | -2.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|